UBS AM’s BioXcel Therapeutics BTAI Stock Holding History

UBS AM’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-857	Closed	-$294K	–	2681
2022 Q4	$294K	Hold	857	–	–	﹤0.01%	2335
2022 Q3	$162K	Hold	857	–	–	﹤0.01%	2641
2022 Q2	$181K	Hold	857	–	–	﹤0.01%	2594
2022 Q1	$287K	Hold	857	–	–	﹤0.01%	2609
2021 Q4	$279K	Sell	857 -488	-36%	-$209K	﹤0.01%	2698
2021 Q3	$653K	Buy	1,345 +57	+4%	+$25.1K	﹤0.01%	2379
2021 Q2	$599K	Buy	1,288 +250	+24%	+$136K	﹤0.01%	2460
2021 Q1	$716K	Buy	1,038 +225	+28%	+$181K	﹤0.01%	2241
2020 Q4	$601K	Sell	813 -100	-11%	-$77.9K	﹤0.01%	2227
2020 Q3	$633K	Buy	913 +582	+176%	+$437K	﹤0.01%	2027
2020 Q2	$281K	Buy	+331	New	+$216K	﹤0.01%	2298

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

UBS AM's BTAI Position: Q1 2023 in Review

UBS AM sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 857 shares — an estimated $294K sold.

UBS AM first reported a position in BTAI in Q2 2020 and held it in 11 quarters. The position peaked at $716K in Q1 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

UBS AM reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
UBS AM sold 857 BioXcel Therapeutics shares in Q1 2023, an estimated $294K.
UBS AM first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 11 quarters.
UBS AM's BioXcel Therapeutics position peaked at $716K in Q1 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.